Freenome is a biotechnology company dedicated to outpacing cancer through early detection. Their intelligent screening platform utilizes multiomics technology and artificial intelligence, combined with a standard blood draw, to identify cancer in its earliest, most treatable stages. This approach aims to make a significant difference by enabling earlier intervention and improving patient outcomes.